New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on April 7, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alnylam Pharmaceuticals has seen insider activity as Chief Human Resources Officer Melissa McLaughlin sold 1,624 shares of the company’s stock in a transaction valued at $519,014, signaling a notable move within the firm’s executive ranks.
Recent Updates on ALNY stock
Alnylam updated its DemonsTTRate real‑world study of vutrisiran in transthyretin amyloidosis cardiomyopathy, underscoring execution progress and future data that could influence expectations for label expansion, adoption, and competitiveness versus other ATTR‑CM therapies.
Jefferies assumed coverage and cut its price target while downgrading to a more cautious stance, citing concerns that the stock already discounts an aggressive long‑term growth path and limited competitive pressure, putting consensus forecasts at risk if markets or rivals evolve less favorably than implied.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
The score is supported primarily by the fundamental inflection to profitability and strong free cash flow, plus upbeat 2026 growth guidance and pipeline momentum from the earnings call. Offsetting this are elevated leverage and historical volatility, bearish technical trend signals, and a very high P/E that leaves little valuation cushion.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
YTD Price Performance: -16.93%
Average Trading Volume: 1,382,526
Technical Sentiment Signal: Hold
Current Market Cap: $43.81B